COZADD BRUCE C sold $1.5M of JAZZ

COZADD BRUCE C sold 6,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $252.98 ($1.52M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · COZADD BRUCE C
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$JAZZ
Neutral
medium confidence
Mentioned
$JAZZ
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JAZZNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director, with the company stating the sale was under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may note the insider sale as a minor sentiment input, but the 10b5-1 structure limits interpretability as a new fundamental signal.

03

What to watch

The article does not provide context on total insider holdings changes over time, nor any concurrent operational or clinical catalysts for Jazz.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Jazz Pharmaceuticals plc.

Company-level read

Ticker impact

$JAZZNeutralMedium confidence
Context

Jazz Pharmaceuticals director COZADD BRUCE C sold 6,000 shares in an open-market transaction for about $1.52M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, which typically reduces the signal strength versus discretionary selling.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Jazz Pharmaceuticals plc

    Subject of the Form 4 insider transaction disclosure.

  • COZADD BRUCE C

    Director who sold 6,000 shares on 2026-08-03.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JAZZMedAI 8/10

Jazz Pharmaceuticals PLC (JAZZ) (Q3 2026) Earnings Call Highlights: Record

Jazz Pharmaceuticals (JAZZ) reported Q3 2026 earnings, raising guidance driven by strong Xywav performance and removing downside scenarios in other segments. Challenges include competitive headwinds for Zepzelca and measured Modeyso revenue growth. Ziihera showed strong community adoption, with 80% of new orders from community accounts. Xywav saw 12% growth and 425 net patient adds, with no expected impact from generics.